---
layout: default
title: Abemaciclib
parent: 僅模型預測 (L5)
nav_order: 12
evidence_level: L5
indication_count: 0
---

# Abemaciclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Abemaciclib (DB12001): Drug Repurposing Evaluation — TxGNN Predictions Pending

---

## One-Sentence Summary

Abemaciclib is a selective CDK4/6 inhibitor currently marketed in Malaysia for breast cancer treatment.
The current Evidence Pack contains **no TxGNN-predicted new indications**, and critical data including mechanism of action, approved indication text, and safety warnings are all listed as unresolved data gaps.
A complete repurposing evaluation **cannot be performed** until these gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Details pending (license text not returned in current data pull) |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (model predictions not yet generated) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

There are currently **no TxGNN-predicted new indications** for Abemaciclib in this Evidence Pack. Without a target indication, a mechanistic rationale for repurposing cannot be constructed.

Abemaciclib is known to function as a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators of the G1-to-S cell cycle transition. CDK4/6 inhibition results in cell cycle arrest in cancer cells that retain an intact Rb (retinoblastoma protein) pathway. However, detailed MOA data has been flagged as a data gap (DG002) in the current pack, and without a predicted target indication, no mechanistic bridge analysis can be performed.

Once TxGNN predictions are generated, the shared pathway biology between the original breast cancer indication and any new predicted indication can be systematically assessed. Given CDK4/6's broad involvement in proliferative signalling across multiple tumour types, repurposing opportunities across other solid tumours or haematological malignancies are plausible hypotheses to explore.

---

## Clinical Trial Evidence

No predicted indication is available in the current Evidence Pack. Indication-specific clinical trial evidence cannot be presented at this stage.

---

## Literature Evidence

No predicted indication is available in the current Evidence Pack. Indication-specific literature evidence cannot be presented at this stage.

---

## Malaysia Market Information

The NPRA query (2026-03-27) confirmed **3 active registrations**. However, the current data pull did not return detailed product records (authorization numbers, product names, dosage forms, or approved indication text). A supplementary NPRA data pull is required.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| — | — | — | Details pending |

> **Note:** 3 registrations confirmed via NPRA query. Full details require re-query or manual retrieval from the NPRA portal.

---

## Cytotoxicity

Abemaciclib is an antineoplastic targeted therapy (CDK4/6 inhibitor class), and the following summarises its cytotoxicity profile based on drug class characteristics.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — selective CDK4/6 inhibitor (not conventional cytotoxic) |
| Myelosuppression Risk | Moderate — neutropenia is the most commonly reported haematological adverse event for this drug class |
| Emetogenicity Classification | Low |
| Monitoring Items | CBC with differential count, liver function tests (ALT/AST), renal function, serum creatinine; monitor for diarrhoea and venous thromboembolism |
| Handling Protection | Follow institutional guidelines for targeted oral oncology agents; standard precautions apply |

---

## Safety Considerations

Safety data (key warnings and contraindications) were not available in the current Evidence Pack and are flagged as a blocking data gap (DG001). No drug-drug interactions were identified in the DDI query.

> Please refer to the approved NPRA package insert for complete safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Abemaciclib (DB12001) is critically incomplete — TxGNN predictions have not yet been generated, and two unresolved data gaps (DG001: NPRA package insert warnings/contraindications; DG002: mechanism of action) block both the safety pre-screening and the mechanistic plausibility analysis. No repurposing evaluation can be completed in this state.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Download and parse the NPRA package insert PDF to extract approved indication text, key warnings, and contraindications
- **[DG002 — High]** Query the DrugBank API (DB12001) to retrieve detailed mechanism of action data
- **[TxGNN Predictions]** Complete the TxGNN prediction run for Abemaciclib and populate `predicted_indications`
- **[License Details]** Re-run the NPRA data pull to retrieve full product names, dosage forms, and authorization numbers for all 3 registered products
- **Re-issue Evidence Pack** after resolving DG001 and DG002 to enable full evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

